Trial Profile
A trial to determine multiple sclerosis disease activity during pregnancy in women who stopped natalizumab >3 months prior to the last menstrual period (LMP) or stopped natalizumab during the last 3 months before the last menstrual period or stopped natalizumab after the last menstrual period but before the second trimester
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 10 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology